We recently demonstrated the existence of speci®c patterns of somatic mitochondrial DNA (mtDNA) mutations in several cancers. Here we sought to identify the presence of mtDNA mutations in prostate cancer and their paired PIN lesions. The D-loop region, 16S rRNA, and the NADH subunits of complex I were sequenced to identify mtDNA mutations in 16 matched PIN lesions and primary prostate cancers. Twenty mtDNA mutations were detected in the tumor tissue of three patients. Identical mutations were also identi®ed in the PIN lesion from one patient. This patient with multiple point mutations also harbored a high frequency of microsatellite instability (MSI-H) in nuclear mononucleotide repeat markers. Remarkably, identical mutations were also detected in all (3/3) matched urine and plasma samples obtained from these patients. Although mitochondrial mutations are less common in prostate adenocarcinoma, they occur early in cancer progression and they can be detected in bodily¯uids of early stage disease patients. The identi®cation of MtDNA mutations may complement other early detection approaches for prostate cancer. Oncogene (2001) 20, 5195 ± 5198.
Introduction
Prostate cancer is the most commonly diagnosed cancer among men in most Western countries and a leading cause of cancer-related mortality in the USA. (Landis et al., 1999) Surgery remains one of the most eective treatment modalities for this disease. Since the likelihood of cure relies mainly in the early detection of the tumor (i.e., while still con®ned within the prostatic capsule), the development of novel and more eective detection techniques for early-stage prostate cancer is becoming increasingly important.
A number of genes have been found to be mutated in prostate cancer. However, these alterations have been consistently found either just in a small number of cases, including ras oncogenic activation and TP53 inactivation (Isaacs and Isaacs, 1996) , or predominantly in advanced disease, such as PTEN inactivation. (Cairns et al., 1997) Thus, one major challenge is to identify more frequent genetic alterations in early stages of the disease, and in premalignant lesions like prostate intraepithelial neoplasia (PIN), to allow DNAbased detection of this major tumor type (Isaacs et al., 1996) .
Recently, we as well as others have demonstrated the existence of speci®c mutation patterns in the mtDNA of various cancers. (Fliss et al., 2000; Polyak et al., 1998) In some cases these mutations may lead to abnormal metabolic and apoptotic processes in neoplastic cells (Green and Reed, 1998) . Indeed, mutational hot spots within protein-coding regions, namely in the NADH dehydrogenase subunits 3, 4 and 5 from complex I, were identi®ed in colorectal and renal tumors (Polyak et al., 1998; Horton et al., 1996) . Furthermore, the non-coding displacement-loop region (D-loop) was found to be a mutational hot spot in bladder, lung, and head and neck neoplasms. (Fliss et al., 2000) Mutations in this region may be related to the function of the D-loop as a regulatory site for both replication and expression of the mt genome (Fliss et al., 2000) . Interestingly, most of the mtDNA mutations were shown to be homoplasmic and could be readily detected in paired bodily¯uids obtained from aected patients (Fliss et al., 2000) . The present study was undertaken to determine whether mitochondrial mutations could be detected in prostatic adenocarcinoma, paired PIN lesions, voided urine specimens, and plasma samples. We thus, sequenced the D-loop region, 16S rRNA and Complex I in these primary tumors and identi®ed 20 mtDNA mutations in three prostate cancers and one matched PIN lesion. Subsequently we detected mutant mtDNA in the urine and plasma of these aected patients.
Results and discussion
We sequenced the mtDNA D-loop region and NADH dehydrogenase in 16 matched PIN lesions, primary prostate tumor, and the corresponding paired lymphocytes ( Figure 1 ). We found 20 somatic mutations, detected in three of the 16 patients examined (Table 1 ). All the somatic mutations detected were homoplasmic or near homoplasmic (Figure 1 ), con®rming results from previous studies, in which the mutated mtDNA became the dominant population in tumor cells (Fliss et al., 2000; Polyak et al., 1998) . In addition, 96 polymorphisms were identi®ed of which 27 were not previously described (Table 2) (Andrew et al., 1999) . We ampli®ed relatively large PCR products (2.5 ± 3.2 kb), in order to avoid ampli®cation of nuclear encoded pseudogenes (Parfait et al., 1998) . All the primer sets used in this study produced no PCR products in a cell line without mtDNA. We also applied a more sensitive oligonucleotide mismatch ligation assay to con®rm mutated sequences in tumor DNA, and a negative signal was always found in the matched lymphocyte DNA.
The excessive exposure of mtDNA to reactive oxygen species (ROS), generated during OXPHOS, results in extensive oxidative damage consistent with Tto-C and G-to-A mutations (Cadet et al., 1997) . In our study, only nine out of the 20 mutations identi®ed (45%) were T-to-C and G-to-A base transitions, potentially indicating less exposure to ROS-derived mutagens in this type of tumor. However, one patient's tumor harbored most of the observed mutations (case 1), probably biasing the mutation distribution. This patient presented multiple mutations widely distributed across various mitochondrial regions, suggesting the possible accumulation of mtDNA damage during tumorigenesis from endogenous factors ( Figure 1a ). Alternatively, these multiple mutations are the result of a limited but catastrophic mutagenic eect from a severe exogenous exposure (Croteau and Bohr, 1997). Intriguingly, this patient worked for many years at a chemical plant.
It has been previously shown that mtDNA instability may be correlated with nuclear genome instability, thereby suggesting that de®ciencies in mismatch repair genes may also aect mtDNA (Habano et al., 1998) . Since repeat sequence instability has been described in the mtDNA of patients with putative mismatch repair de®ciency, we evaluated the status of the nuclear genome in patient 1, analysing several common mononucleotide repeat markers (BAT-25, BAT-26, BAT-34C4 and BAT-40). We found allelic size variation (microsatellite instability) for BAT-25 and BAT-26 in the PIN lesion and paired adenocarcinoma DNA (data not shown) suggesting an impairment of the mismatch repair system. Because another tumor (patient 46) harbored an A-tract one base pair deletion, the status of the nuclear genome in this patient was also analysed with the same common mononucleotide repeat markers but no evidence of widespread genetic instability was found (data not shown).
In the patient with multiple tumor mutations all of the mutations found in the primary tumor sample were also detected in the PIN lesion, providing further evidence for the precursor nature of PIN in relation to prostatic adenocarcinoma. Since all the mutations were Tumor speci®c molecular abnormalities can be detected in many bodily¯uids and have been investigated as a diagnostic tool in several tumor types (Sidransky, 1997) . We tested paired bodily¯uids and found that mutant mtDNA could be detected in the urine and plasma samples from all three patients that harbored mutated mtDNA in the primary tumors (Figure 2 ). This result is supported by the homoplasmic nature of the somatic mutations detected in the primary tumor, providing an unprecedented detection advantage due to the high copy number of mutant mtDNA in neoplastic tissue (Fliss et al., 2000; Polyak et al., 1998; Wallace et al., 1999) .
However, the mutated mtDNA was still clearly dilute in all paired urine and plasma samples ( Figure  2 and data not shown) suggesting that very little neoplastic DNA is shed (and/or survives) from the prostatic epithelium to the urine or blood, at least in early stage prostatic adenocarcinoma. This observation is supported by our recent study suggesting that a nuclear molecular target (hypermethylation of GSTP1), is also challenging to detect in paired serum and urine from prostate cancer patients (Cairns et al., 2000) . These results also stand in stark contrast to the ease of urine detection for bladder cancer based on microsatellite DNA analysis, (Mao et al., 1996; Steiner et al., 1997) .
We have found that mtDNA mutations are a relatively rare event in prostate cancer. In at least one case, identical mtDNA mutations were found in a precursor PIN lesion suggesting that mtDNA mutations can occur early in the neoplastic process. Although limited by their low prevalence in prostate cancer, mtDNA mutations identi®ed in primary tumors may aid as sensitive markers for detection of residual tumor burden or minimal disease, after primary cancer resection.
Materials and methods
Sixteen patients with clinically localized prostate adenocarcinoma (stage T1c), consecutively diagnosed and treated with radical prostatectomy at the Portuguese Cancer Institute were selected for this study. From each patient, fresh prostatic tissue was collected and snap-frozen in isopentane, immediately after resection and in an orderly fashion, enabling topographic correlation with the tissue submitted for routine processing (formalin ®xation and paran embedding). Frozen sections were subjected to light microscopy observation after haematoxylin-eosin staining by two pathologists. Areas of benign epithelium, PIN and adenocarcinoma were identi®ed and carefully microdissected from 12-mm thick sections. An average of 50 sections for each area was used. From samples of peripheral blood, plasma was separated, and lymphocytes were collected and used as source of normal DNA. Samples of voided urine were also obtained. DNA was extracted from all the samples (tissue, lymphocytes, plasma, and urine) as previously described. Brie¯y, DNA was digested overnight at 488C in 1% SDS/Proteinase K (0.5 mg/ml), extracted by phenol-chloroform, and ethanol precipitated (Ahrendt et al., 1999) . In order to avoid possible contamination from nuclearencoded pseudogenes, fragments with more than 2.5 kb in length containing the D-loop region, 16S rRNA, and the NADH dehydrogenase subunits (from ND1 to ND6), were ampli®ed using the overlapping primers designed by Polyak et al. (1998) . In a PCR buer containing 6% DMSO, approximately 300 ng of genomic DNA was subjected to a step-down PCR protocol: 948C 30 s, 648C 1 min, 708C 3 min, 3 cycles, 948C 30 s, 618C 1 min, 708C 3 min, 3 cycles, 948C 30 s, 588C 1 min, 708C 3.5 min, 15 cycles, 948C 30 s, 578C 1 min, 708C 3.5 min, 15 cycles, and a ®nal extension at 708C for 5 min. PCR products were gel-puri®ed using a Qiagen gel extraction Kit (Qiagen Inc., Valencia, CA, USA) and sequenced using a (g-33 P) ATP 5' end-labeled sequencing primer and the AmpliCycle sequencing kit (Perkin-Elmer, Roche Molecular Systems Inc., Brachburg, NJ, USA), under the following cycle conditions: 958C 30 s, 528C 1 min, 708C 1 min for 30 cycles. The sequenced products were analysed on a denatured 6% polyacrylamide gel. In each experiment, DNA extracted from a mtDNA-negative osteosarcomaderived cell line was included, as a negative control.
Owing to the low concentration of DNA in the urine and plasma samples, mtDNA mutations were not detected using sequence analysis alone. Thus, a more sensitive oligonucleotide mismatch ligation assay was performed, as described by Jen et al. (1994) . In short, fragments containing mutations were PCR-ampli®ed using standard conditions and ethanol precipitated. For each mutation, discriminating oligonucleotides that contained the mutated base at their 3' end were designed (position: 12414, 5'-TTTTGTTG-3' for patient 1, position: 2923, 5'-GGAACAAA-3' for patient 32, and position: 11032, 5'-CACGAAAAAA-3' for patient 46). An immediately adjacent 3' oligonucleotide linker, along with the discriminating oligonucleotide (5'-GGGTTAACGAG-3' for patient 1, 5'-TTACCCTAGGG-3' for patient 32 (5'-AA-CAATTACCC-3'), and 5'-CTCTACCT-3' for patient 46) were used as substrate for the ligation reaction. In addition a blocking oligo was used for the ligation reaction in samples from patient 32. Discriminating oligonucleotides (40 ng) were mixed with the PCR reaction mixture and 40 ng of the [ 32 P] end-labeled 3' oligonucleotide linker. The reactions were incubated at 378C for 1 h, in the presence of T 4 DNA ligase (Life Technologies, Long Island, NY, USA), analysed on denatured 12% polyacrylamide gels, and processed by autoradiography.
